University Medical Center Groningen (UMCG) and SHINE Europe have secured a 10.5 million euro ($11 million) grant to advance European production of terbium isotopes for cancer treatments. 17 October 2024
Danish dermatology focused LEO Pharma has announced the launch of Anzupgo (delgocitinib) cream in Germany for the treatment of adult patients with moderate to severe chronic hand eczema (CHE), for whom topical corticosteroids are inadequate or inappropriate. 15 October 2024
French pharma major Sanofi revealed it has entered into negotiations with private equity firm Clayton Dubilier & Rice (CD&R) for the potential sale of a 50% controlling stake in Opella, its consumer healthcare business. 14 October 2024
The UK’s new 2024 voluntary scheme for branded medicines pricing, access, and growth (VPAG) came into force at the beginning of January this year. 4 October 2024
French drugmaker Mitem Pharmavhas the worldwide acquisition of Desferal (deferoxamine), a major MITM in hematology, from Swiss giant Novartis. 25 September 2024
The Austrian Academy of Sciences (OeAW) is further expanding its focus on life sciences by opening an institute for biomedical artificial intelligence (AI) based on a 150 million euros ($166.8 million) funding from the German non-profit Boehringer Ingelheim Foundation (BIS). 18 September 2024
Novartis is building two new radioligand therapy (RLT) manufacturing facilities in the USA to enhance its supply chain for cancer treatments. This move supports the growing use of RLTs, a form of precision medicine that targets tumors with radiation. 6 September 2024
Belgium’s largest drugmaker UCB announced a strategic divestment deal in China, underscoring its strategic shift towards innovation and partnership in one of the world’s fastest-growing pharmaceutical markets. 27 August 2024
The UK’s largest pharma company AstraZeneca has rejected claims that it is moving its vaccine operations to the USA, according to media reports. 23 August 2024
Mitsubishi Tanabe Pharma announced the termination of its exclusive sales rights agreements with AnGes for the HGF gene therapy product, Collategene (beperminogene perplasmid) intramuscular injection targeting peripheral arterial diseases in Japan and the USA. 23 August 2024
UK pharma major AstraZeneca has become the only current UK-lis¬ted company to reach a £200 billion ($256.4 billion) valuation, the Financial Times reported today, noting that it is a vindication of the company’s bet on developing a leading portfolio of cancer drugs. 14 August 2024
US pharma giant Pfizer has announced the publication of real-world results from a cohort of the longitudinal, observational Phase IV THAOS (Transthyretin Amyloidosis Outcomes Survey) study in the Journal of Cardiac Failure. 8 August 2024
Japanese drugmaker Shionogi says that its New Drug Application (NDA) for cefiderocol has been accepted for review by the Center for Drug Evaluation, National Medical Products Administration (NMPA). 5 August 2024
Germany’s Bayer has submitted to the US Food and Drug Administration for approval to market elinzanetant for moderate to severe vasomotor symptoms (VMS), commonly known as hot flashes, associated with menopause. 2 August 2024
Spanish plasma-derived medicines company Grifols announced with the Andorran government the cancellation of the immunology research center planned for the parish of Ordino. 29 July 2024
The US Food and Drug Administration (FDA) approved Palforzia (peanut [Arachis hypogaea] allergen powder-dnfp] to include initiation of treatment, up-dosing and maintenance in individuals ages one through three years. 27 July 2024
Vividion Therapeutics, a wholly-owned subsidiary of Germany’s Bayer, today announced it will expand its global innovation capabilities with a new research and development (R&D) center and corporate headquarters in San Diego, California. 23 July 2024
US pharm major Eli Lilly on Friday revealed via a social media posting that it has been granted approval from the Chinese National Medical Products Administration (NMPA) to sell tirzepatide for weight loss in the country. 20 July 2024
The US Food and Drug Administration (FDA) issued a draft guidance for industry, “Pediatric Inflammatory Bowel Disease: Developing Drugs for Treatment,” to help sponsors in the clinical development of drugs to treat pediatric patients with inflammatory bowel disease (IBD). 19 July 2024
The Indian Institute of Technology (IIT) Kanpur has licensed a gene therapy technology to Mumbai-based Reliance Life Sciences that could change the landscape of gene therapy, particularly for genetic eye diseases. 13 March 2023
Swedish rare disease company Calliditas Therapeutics has announced positive Phase III results for Tarpeyo (budesonide) in primary IgA nephropathy (IgAN). 13 March 2023
Shares of US drug developer Intercept Pharmaceuticals closed almost 14% lower at $16.12 on Friday, after it revealed that the US regulator will hold an advisory committee meeting to review its re-submitted approval request for its investigational non-alcoholic steatohepatitis (NASH) treatment obeticholic acid (OCA). 13 March 2023
On Friday, the US Food and Drug Administration (FDA) issued a notice addressing the agency’s COVID-19-related guidance documents, including which of those guidance documents will no longer be in effect after the expiration of the COVID-19 public health emergency (PHE) declared under the Public Health Service (PHS) Act, and which of those guidance documents the FDA is revising to temporarily continue in effect. 13 March 2023
Fiocruz, Brazil’s scientific institution for R&D, and the Drugs for Neglected Diseases Initiative (DNDi) have signed a strategic alliance agreement, which expands and strengthens the relationship between the two institutions. 13 March 2023
The US Food and Drug Administration (FDA) has approved Daybue (trofinetide) for the treatment of Rett syndrome in adult and pediatric patients two years of age and older. 11 March 2023
Spanish privately owned drugmaker Esteve says it has now obtained pricing and financing for an inhaled treatment for OFF periods in Parkinson's disease, which it launched on the Spanish market in mid-February 2023. 11 March 2023
Keen to accelerate vaccine drug development and approvals in India, an expert committee of India's Central Drugs Standard Control Organization (CDSCO) met recently to review the research efforts of pharmaceutical companies. 10 March 2023
Pfizer has achieved another regulatory breakthrough, a couple of years on from jointly launching the first mRNA vaccine to reach the market. 10 March 2023
ModeX Therapeutics, an OPKO Health company, has entered into an exclusive worldwide license and collaboration agreement with Merck & Co for the development of MDX-2201, ModeX’ pre-clinical nanoparticle vaccine candidate targeting Epstein-Barr virus (EBV). 9 March 2023
Privately-held Swiss drugmaker Ferring was responsible for two out of the eight biological medicines approved by the US Food and Drug Administration’s (FDA) Center for Biologics Evaluation and Research in 2022. 9 March 2023
The Indian government is seeking to overhaul the patent rules in the country to spur innovation and research and development (R&D). Minister for Commerce and Industry Piyush Goyal said the commitment to quality will transform manufacturing in the country. 8 March 2023
Stalicla, a Swiss company specializing in the identification of specific phenotypes of autism spectrum disorder (ASD) has entered into a Cooperative Research and Development Agreement (CRADA) with the US National Institute on Drug Abuse (NIDA), part of the US National Institutes of Health (NIH). 8 March 2023
There will be changes impacting drugmakers doing business in Northern Ireland as a result of February’s Windsor Framework agreement between the UK and European Union (EU). 7 March 2023
Shorla Oncology, a privately-held, female founded US-Ireland pharmaceutical company, today announced that the US Food and Drug Administration (FDA) has approved the company’s oncology drug, Nelarabine Injection, for the treatment of T-cell acute lymphoblastic leukemia and T-cell lymphoblastic lymphoma. 7 March 2023
Shares in US pharma giant Merck & Co jumped 4% on Monday, an unusual result for a big pharma, reflecting the level of excitement over its latest data release. 7 March 2023
Spanish producer of blood plasma-based products Grifols saw its shares fall 3.7% to 10.94 euros by close of trading today, after it announced a global collaboration and licensing agreement with Selagine, a US company focused on developing novel therapeutics for ocular diseases, to treat dry eye disease (DED) with immunoglobulin eye drops. 6 March 2023